Comparison of Magnetic Resonance and Endoscopic Retrograde Cholangiopancreatography in Malignant Pancreaticobiliary Obstruction

Steve K. Georgopoulos, MD; Lawrence H. Schwartz, MD; William R. Jarnagin, MD; Hans Gerdes, MD; Ira Breite, MD; Yuman Fong, MD; Leslie H. Blumgart, MD; Robert C. Kurtz, MD

Hypothesis: We hypothesize that magnetic resonance cholangiopancreatography (MRCP) is comparable to endoscopic retrograde cholangiopancreatographic (ERCP) as a diagnostic tool in patients with malignant biliary obstruction.

Design: Eighteen patients with suspected pancreaticobiliary malignancy were evaluated by ERCP and MRCP in 8 months (March 1, 1996, to October 31, 1996). Magnetic resonance cholangiopancreatography was performed with a 1.5-T scanner using 4-mm slices. Images were obtained in a 14- to 28-second breath-hold. Images from MRCP were retrospectively evaluated by a radiologist for image quality, ductal dilation, level of obstruction, and overall diagnostic impression. Images from ERCP were retrospectively evaluated by a biliary endoscopist (L.H.S.) and served as the standard for calculating sensitivity, specificity, and positive predictive values. In addition, intraoperative findings were compared with MRCP results in all patients explored.

Results: Diagnostic-quality MR images were obtained in 18 patients (100%). Diagnostic-quality endoscopic images were obtained in 16 (89%) of 18 attempted biliary cannulations and 11 (78%) of 14 attempted pancreatic cannulations. Magnetic resonance CP accurately delineated the level of extrahepatic biliary ductal obstruction in 13 (87%) of 15 patients. More important, MRCP provided valuable staging information in most patients. Findings from MRCP correlated with operative findings (size and location of tumor and mesenteric vascular involvement) in 8 (80%) of 10 patients who underwent surgery, while failing in 2 patients (20%) with carcinomatosis.

Conclusions: Magnetic resonance CP is a sensitive study for detecting the presence and level of biliary ductal obstruction in patients with cancer. The results are comparable to those of ERCP; however, MRCP provides additional data regarding extent of disease that is not available from ERCP alone.

Arch Surg. 1999;134:1002-1007

AFTER ITS introduction in the 1970s, endoscopic retrograde cholangiopancreatography (ERCP) revolutionized the diagnosis and management of pancreaticobiliary diseases. It remains the gold standard imaging study for visualizing the pancreatic and distal bile ducts. Conversely, ERCP is an invasive, often difficult, operator-dependent procedure that is associated with relatively frequent complications (≤5%).1 In addition, ERCP provides little if any information regarding the extent of disease, a critical consideration in planning therapy for patients with cancer. To obtain such information, ERCP must be combined with other imaging studies, usually abdominal computed tomographic scanning.

Surgery remains the primary therapy for nearly all pancreaticobiliary cancers. The resectability of these tumors has been notoriously low, however, resulting in many unnecessary explorations.2,3 Although laparoscopy has had a major impact in allowing more accurate staging and identification of unresectable disease with less morbidity, patients are not spared the potential risks of general anesthesia and a highly invasive procedure.4 Noninvasive preoperative imaging that more accurately determines the extent of disease would represent a significant advance.

See Invited Critique at end of article

This article is also available on our Web site: www.ama-assn.org/surgery.
Magnetic resonance cholangiopancreatography (MRCP) is a relatively new, noninvasive, non-operator-dependent imaging technique for evaluating pancreaticobiliary diseases. Projectional images similar to direct cholangiograms or pancreatograms are obtained without the use of contrast. In addition to high-quality images of the biliary and pancreatic ducts, MRCP can provide important diagnostic information regarding tumor size and character (solid vs. cystic), vascular invasion, or metastatic disease. Since first reported in 1991, modifications in fast MR techniques have improved image quality and have demonstrated high sensitivity and specificity for evaluating a variety of diseases. Whether MRCP will supplant standard imaging studies in patients with malignant biliary obstruction remains an open question.

RESULTS

IMAGE QUALITY

Diagnostic-quality MRCP images were obtained in all 18 patients. In 16 (89%) of 18 patients, ERCP provided adequate cholangiograms but failed in 2 patients (11%) because of difficulty cannulating the bile duct. Successful cannulation and imaging of the pancreatic duct was achieved in 11 (78%) of 14 patients. Three patients were considered technical failures (pancreatic duct could not be cannulated), and cannulation was not attempted in 4 patients. Two ERCP-related complications—pancreatitis (1 patient) and retroperitoneal duodenal perforation (1 patient)—were resolved completely with medical therapy.
Figure 1. A, Endoscopic cholangiogram demonstrating extrinsic compression of the distal common bile duct. The pancreatic duct could not be visualized. B, Magnetic resonance cholangiopancreatogram in the same patient revealed a cystic neoplasm in the head of the pancreas, causing biliary obstruction (small white arrow). A dilated pancreatic duct (small black arrow) and a dilated gallbladder (large white arrow) are also shown.

Figure 2. A, Endoscopic cholangiogram showing a distal common bile duct stricture (arrow). No pancreatogram was obtained. B, Magnetic resonance cholangiopancreatogram in the same patient identifying a mass in the pancreatic head (large white arrow) causing biliary (small black arrow) and pancreatic (large black arrow) ductal obstruction (“double duct sign”). A dilated gallbladder is also shown (small white arrow).

Figure 3. A, Endoscopic retrograde cholangiopancreatogram showing a dilated common bile duct consistent with previous cholecystectomy and a normal pancreatic duct. Slight evidence of an incompletely filled right posterior sectorial hepatic duct (arrow). B, Sagittal magnetic resonance cholangiopancreatographic (MRCP) reconstruction in the same patient revealing a right hepatic lobe mass (small arrow) compressing the right posterior sectorial hepatic duct (large arrow). C, A more anterior MRCP reconstruction further defining the relationship between the mass (large arrow), the right posterior sectorial hepatic duct (small arrow), and the main right hepatic duct (immediately to the left of the tumor).
DUCTAL DILATION

Images from MRCP had slight evidence of pancreatic ductal dilation in 5 patients, 2 of which were thought to be of normal caliber on ERCP (100% sensitivity, 75% specificity, and 60% positive predictive value). In 3 patients who failed endoscopic pancreatography, MRCP demonstrated not only pancreatic ductal dilation but also the underlying cause (Figure 1 and Figure 2). Images from MRCP diagnosed intrahepatic biliary ductal dilation in 14 patients; ERCP confirmed 12 of these (100% sensitivity, 50% specificity, and 77% positive predictive value). In 10 patients, MRCP correctly identified extrahepatic biliary ductal dilation but misdiagnosed 3 of 6 patients with nondilated ducts (100% sensitivity, 50% specificity, and 77% positive predictive value). By contrast, MRCP identified a peripancreatic mass causing biliary ductal obstruction in 2 patients who failed endoscopic cholangiography. In a third patient with hepatocellular cancer, MRCP demonstrated a mass as the cause of right posterior sectorial hepatic duct obstruction (Figure 3). Also, in 1 patient without ductal dilation on ERCP, MRCP revealed a mass in the uncinate process of the pancreas.

LEVEL OF OBSTRUCTION

Two patients had obstruction of the proximal bile ducts. In 13 (87%) of 15 patients, MRCP correctly identified the level of biliary ductal obstruction compared with ERCP findings: 12 (92%) of 13 patients with mid-distal ob-

struction (92% sensitivity, 67% specificity, and 92% positive predictive value) and 1 (50%) of 2 with proximal obstruction (50% sensitivity, 100% specificity, and 100% positive predictive value).

EXTENT OF DISEASE
AND ASSESSMENT
OF RESECTABILITY

Correlation of MRCP results with operative findings was possible in 10 patients (Table 2), 3 of whom had clearly unresectable disease but underwent palliative procedures. Seven patients had apparently resectable tumors: 5 subsequently underwent complete resection and 2 had carcinomatosis and therefore did not undergo resection. Overall, MRCP correctly predicted

---

Table 2. Disposition of 18 Patients Based on Preoperative Investigations

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Surgery Group (n = 10)</th>
<th>No Surgery Group (n = 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, No.</td>
<td>Finding</td>
<td>Patients, No.</td>
</tr>
<tr>
<td>Palliative</td>
<td>Superior mesenteric</td>
<td>3</td>
</tr>
<tr>
<td>Curative</td>
<td>artery/ceeliac</td>
<td></td>
</tr>
<tr>
<td>Complete resections</td>
<td>Encasement</td>
<td>5</td>
</tr>
<tr>
<td>Unresectable</td>
<td>Metastatic disease</td>
<td>2</td>
</tr>
<tr>
<td>(carcinomatosis)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Figure 4. Magnetic resonance cholangiopancreatogram showing pancreatic adenocarcinoma clear of (A and B) and invading (C and D) the mesenteric vessels. A. Gadolinium-enhanced T1-weighted image showing a pancreatic tumor (small arrow) and a clear, uninvolved tissue plane around the adjacent superior mesenteric vein and artery (large arrow). B. T1-weighted image at the same level again showing the mass (white arrow) clear of the superior mesenteric artery and vein (black arrow). C. T2-weighted image demonstrating the tumor (small arrow) encasing the superior mesenteric artery (large arrow). D. Gadolinium-enhanced T1-weighted image at the same level again showing tumor encasement of the superior mesenteric artery (arrow).
therapy.13,14 Assessment for regional lymph nodal and dis-
complete resection remains the only potentially curative
sectability should be the primary initial objective because
patients with pancreaticobiliary tumors, determining re-
creaticobiliary cancers; as in all patients with cancer, ac-
All study patients had either primary or secondary pan-
sion in 4) (invasion in 1 and no inva-
and MRCP correctly predicted the extent of vascular
involvement by tumor was performed in 6 patients,
operative assessment of hilar or mesenteric vascular
extent of disease in 8 (80%) of 10 patients. Intra-
operative assessment of hilar or mesenteric vascular
involvement by tumor was performed in 6 patients,
and MRCP correctly predicted the extent of vascular
involvement in 5 patients (invasion in 1 and no inva-
) (Figure 4). In 1 patient, tumor adherence
to the lateral wall of the portal vein was not noted
before surgery.

Two patients had extrinsic compression of the com-
 bile duct by enlarged, tumor-bearing lymph nodes. Whereas ERCP had slight evidence of such a possibility
in 1 patient, MRCP demonstrated this finding clearly in
both (Figure 5).

DIAGNOSTIC IMPRESSION

After reviewing each study, masked reviewers recorded
their impressions of the most likely diagnoses. Diagnostic
impressions based on MRCP correlated with those from
ERCP in 15 (83%) of 18 patients. There was disagree-
ment in 3 patients, only 1 of whom subsequently under-
went surgery. Results of ERCP proved more accurate in
this case.

COMMENT

All study patients had either primary or secondary pan-
creaticobiliary cancers; as in all patients with cancer, ac-
curate disease staging is essential for planning therapy. In
patients with pancreaticobiliary tumors, determining re-
sectability should be the primary initial objective because
complete resection remains the only potentially curative
therapy.13,14 Assessment for regional lymph nodal and dis-
tant metastases is obviously an important consideration.
In addition, the relationship between these tumors and ma-
or mesenteric and hepatic hilar vessels is a critical deter-
ninant of resectability and requires careful evaluation.

The true measure of worth of an imaging study in
this patient population lies in its ability to accurately as-
ss the extent of disease and to reliably demonstrate un-
sectable disease preoperatively. Other factors, such as
morbidly to the patient, need for additional studies, and
cost must also be considered.

As an emerging technique for imaging the biliary and
pancreatic ducts, MRCP must be critically evaluated be-
fore standard diagnostic studies are abandoned. Direct
comparison of MRCP to established diagnostic methods
is an important initial step in this process. Correlation
of MRCP results with intraoperative findings, however,
will ultimately determine its value.

Results of this study confirm the ability of MRCP
to detect biliary and pancreatic ductal dilation with great
sensitivity, show that the overall diagnostic impression
based on MRCP correlate closely with that of ERCP, and
demonstrate the capacity of MRCP to assess disease ex-
ten. Ten patients were predicted to have unresectable
disease, which was confirmed at surgery in 3 and by needle
biopsy examination in 5. Seven patients were predicted
to have resectable tumors; 5 underwent complete resec-
tion. Furthermore, MRCP provided accurate information
regarding the extent of vascular involvement in 5 of 6 patients, failing to detect portal vein adherence in
only 1. In 8 of 10 patients who underwent surgery, MRCP
correctly predicted the extent of disease. Two cases of
carcinomatosis, notoriously difficult to detect before sur-
gery, were missed. Previous studies6-12 of MRCP, al-
though documenting the sensitivity of detecting biliary
and pancreatic ductal dilation, have not correlated the
results to intraoperative findings.

Thus, MRCP combines accurate images of the bili-
ary and pancreatic ducts and adjacent extraductal struc-
tures. The implications are clear. First, many patients
might avoid ERCP and its associated morbidity—not only
procedure-related complications but also postsurgical
 complications related to contaminated bile. There is now
substantial evidence that preoperative biliary intuba-
tion does not improve outcome after surgery.15,16 and ac-
tually increases the incidence of bile contamination and
postoperative complications.17,18 Many of these stents are
placed to prevent cholangitis after injecting contrast above
a stenotic bile duct, a practice that MRCP may substan-
tially reduce. Second, MRCP, as a single study, may pro-
vide all the necessary diagnostic and staging informa-
tion, sparing patients from undergoing multiple studies.

This study demonstrates the great potential of MRCP
and suggests that it will likely evolve into the study-of-
choice in evaluating patients with pancreaticobiliary ma-
lignancies. However, the small number of patients in
this study and others prevents a definitive statement to
this effect. A large, prospective study comparing MRCP
with standard imaging (ERCP plus computed tomographic
scanning), with correlation of both to operative find-
ings, is required. Certainly, MRCP cannot replace the
therapeutic applications offered by direct cholangiogra-
phy. However, by demonstrating unresectable disease and
the level of biliary obstruction, MRCP may help direct
the appropriate intervention (endoscopic vs percutane-
ous biliary intubation).

Reprints: Robert C. Kurtz, MD, Gastroenterology-
Nutrition Service, Department of Medicine, Memorial Sloan-
Kettering Cancer Center, 1275 York Ave, New York, NY
10021 (e-mail: kurtzr@mskcc.org).
REFERENCES


In the past 3½ decades we have witnessed the introduction of multiple new imaging techniques: endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography, transcutaneous ultrasonography, computed tomography (CT), and, most recently, endoscopic ultrasonography and magnetic resonance cholangiopancreatography (MRCP). All techniques have their proponents, and each has inherent advantages and limitations. Currently, there seems to be no universally accepted consensus on the imaging procedure-of-choice in patients with presumed or suspected mechanical biliary obstruction, as either a diagnostic or a staging procedure.

Georgopoulos and colleagues from Memorial Sloan-Kettering Cancer Center, New York, NY, suggest that MRCP might be the optimal diagnostic test (ie, the safest test, with high sensitivity, specificity, and positive predictive value) and should replace ERCP—and I believe they are correct, although this study does not prove it. Results of their preliminary study (only 18 patients) suggest that the noninvasive MRCP is as accurate as the invasive ERCP. This study, however, has several limitations that I am certain the authors would acknowledge. First, small numbers and a wide spectrum of sites of extrahepatic biliary obstruction limit definitive conclusions. Second, there is no comparison with CT (as a diagnostic procedure), which begs the question of whether MRCP was even necessary (if the CT showed a mass and the proximal [hepatic] extent of resection).

These criticisms aside, this study and several recent others1-2 address the use of MRCP for diagnosis of various pancreaticobiliary disorders. What should we conclude? MRCP may well replace diagnostic (but not therapeutic) ERCP in patients with suspected mechanical disorders of the pancreaticobiliary ductal systems—the driving forces are both accuracy (roughly equivalent) and safety (noninvasiveness). Cost and availability are other aspects that will need to be addressed.

Results of this study also attempt to suggest (indirectly) that MRCP adds data important for “staging” local vascular involvement, etc. However, this study, rightfully so with so few patients, does not and cannot pursue this topic. A better study addressing staging is that by Trede and colleagues,3 who believe that MR is superior to CT in staging pancreaticobiliary neoplasms. Further studies with a direct comparison of MR and MRCP with CT (the current gold standard) will be necessary to answer this challenge.

Concerning diagnosis and staging, we as surgeons need to maintain both an open mind and a malleable approach to the evaluation of patients with jaundice; CT, MRCP, staging laparoscopy,4 and peritoneal cytology5 all have potential benefits that may change as new procedures become available.

Michael G. Sarr, MD
Mayo Medical School
Division of General and Gastrointestinal Surgery
Gastroenterology Research Unit (AL 2-435)
Mayo Clinic
200 First St SW
Rochester, MN 55905